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We are moving into a new era of stem cell research where many possibilities for treatment of degenerative, chronic
and/or fatal diseases and injuries are becoming primed for clinical trial. These reports have led millions of people
worldwide to hope that regenerative medicine is about to revolutionise biomedicine: either through transplantation
of cells grown in the laboratory, or by finding ways to stimulate a patient’s intrinsic stem cells to repair diseased
and damaged organs. While major contributions of stem cells to drug discovery, safety and efficacy testing, as well
as modelling ‘diseases in a dish’ are also expected, it is the in vivo use of stem cells that has captured the general
public’s attention. However, public misconceptions of stem cell potential and applications can leave patients
vulnerable to the influences of profit driven entities selling unproven treatments without solid scientific basis or
appropriate clinical testing or follow up. This review provides a brief history of stem cell clinical translation together
with an overview of the properties, potential, and current clinical application of various stem cell types. In doing so
it presents a clearer picture of the inherent risks and opportunities associated with stem cell research translation,
and thus offers a framework to help realise invested expectations more quickly, safely and effectively.
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The immense scientific, media and public interest in
stem cells over the past 15 years has largely been fo-
cused on two areas: the therapeutic potential of stem
cells, and ethical controversies relating to the destruc-
tion of human embryos historically required to obtain
pluripotent stem cells. What is rarely fully appreciated is
the significant research progress made during these years
that has resulted in a large number of stem cell-based
clinical trials currently, or soon to be, underway [1,2]. At
the same time there has also been a rapid increase in the
number and range of unproven stem cell therapies being
offered worldwide. These unproven procedures are
rarely underpinned by strong scientific evidence and are
not tested through rigorous clinical trial assessment,
thus making it difficult to support any claims made by
the providers other than ‘selling hope’. Moreover, these
unproven treatments are marketed directly to patients in* Correspondence: m.oconnor@uws.edu.au
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in any medium, provided the original work is pan attempt to bypass the expert opinion of the patient’s
treating physician(s). The emergence of unproven stem
cell therapies alongside legitimate stem cell clinical trials
neatly highlights the potential and pitfalls inherent
within the stem cell field, both of which are driven by
the desire of patients for desperately needed new treat-
ments. Best management of these critically competing
issues, to enable progress to be made as quickly as pos-
sible without exploitation of vulnerable patients, will be
aided by a clear understanding of how the stem cell field
has developed to where it is now.Stem cell properties underpin their clinical potential
Stem cells can be divided into two broad categories,
tissue-specific (‘adult’) stem cells and pluripotent stem
cells. Both of these stem cell types are able to make
identical copies of themselves during cell division, a
process termed ‘self-renewal’. Importantly, as stem cells
self-renew they retain the ability to produce the more
mature functional cell types of the body, such as nerve,
blood, heart or cartilage cells, through processes broadly
termed ‘differentiation’. Tissue-specific stem cells normallyOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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for example, blood stem cells only produce blood cells. In
contrast, pluripotent stem cells can produce any cell type
of the body. In terms of clinical applications, both tissue-
specific and pluripotent stem cells can be used to generate
cells for autologous (patient-sourced) and allogenic (donor-
sourced) therapies.
The development of clinical stem cell therapies has oc-
curred progressively over the last 50 years, typically via
the ‘medical innovations’ route (Figure 1). Commonly
accepted clinical stem cell treatments are currently lim-
ited to therapies based on hematopoietic, skin, and cor-
neal (limbal) stem cells. The first human hematopoietic
transplant occurred in 1957 with the transplantation of
bone marrow (containing blood stem cells) from one
identical twin to the other in order to treat leukemia [3].
This work ultimately led to the 1990 Nobel Prize in
Physiology or Medicine being awarded to Drs Murray
and Donnall Thomas. However, progress from this first
experimental human transplant to routine clinical ther-
apy took decades of painstaking and publicly-reported
research into the molecular mechanisms of the hema-
topoietic system. This included: discovery of human
leukocyte antigen matching and its importance in
minimization of graft-vs-host disease (GVHD) [4], and
the discovery that hematopoietic stem cells (HSC) could
be more easily obtained from peripheral blood (and sub-
sequently cord blood) to provide less invasive and more
efficacious transplant procedures [5]. As a result of these
concerted international research efforts over 50,000 life-
saving HSC transplants are now routinely performed
worldwide every year [6].
The success of HSC transplants led scientists and cli-
nicians to research stem cell-based therapies for other
tissues. In 1981 skin stem cells were first harvested from
burns patients, amplified in the laboratory and then
transplanted back to the patient to partially reconstitute
their skin [7]. The (limited) success of this initial proced-
ure has led to a large number of skin grafts being per-
formed since [8]. However, more basic research is
needed to improve the quality of the resulting skin so
that it possesses more characteristics of normal skin
such as sweat glands and hair follicles [9,10].
In addition to saving lives, stem cell-based treatments
have also been used to improve lives. In 1997 the first
report was published showing that limbal stem or pro-
genitor cells could be harvested from the edges of the
cornea, proliferated in the laboratory and then trans-
planted back to patients to restore sight after corneal
damage [11]. While improved cell harvest methods, cell
expansion methods, and transplantation substrates are
needed, the current limbal stem cell approach is capable
of restoring sight for some forms of corneal disease and
injury (collectively termed limbal stem cell deficiencies).As a result, this therapy has become widely used particu-
larly in developing countries where corneal injury is
more prevalent [12,13].
Arrival of new cell sources for stem cell therapies
To scientists, doctors, journalists, policy makers and the
public alike it appears self-evident that a primary driver
behind the development of the above three stem cell
treatments was a desire to treat patients with fatal or
chronically debilitating conditions. However, it has to be
recognized that their refinement into effective clinical
therapies, through dramatic improvements in efficacy
and reduced treatment invasiveness, arose as a direct re-
sult of extensive basic research. This research, and its
wide and transparent dissemination, created testable hy-
potheses that were assessed in controlled clinical set-
tings. For example, the successful application of HSC for
lymphopenia, leukemias and lymphomas only became
possible after extensive research provided a detailed mo-
lecular understanding of GVHD [3,4]. For skin and cor-
neal grafts, targeted research into the identification,
harvesting, expansion and transplantation of appropriate
stem/progenitor cells was needed before the treatment
of patients could be attempted [11,14]. Clearly, success-
ful development of these clinical therapies hinged on
continuous evidence-based research to improve treatment
efficacy and safety, and to reduce patient discomfort.
As a result of the clinical achievements made using
hematopoietic, skin and corneal tissue-specific stem
cells, tremendous international research efforts have
been initiated to identify stem cells in other organs of
the body. Tissue-specific stem cells have thus been iden-
tified in most organs [15], helping not only explain the
regenerative capacities of the body but providing new
opportunities for the development of stem cell-based
treatments for diseases and injuries of these tissues
(Table 1). In particular mesenchymal stem or stromal
cells (MSC) identified in a wide range of tissues (includ-
ing adipose tissue, bone marrow, amniotic fluid, umbil-
ical cord, placenta, menstrual blood and dental pulp)
have generated a great deal of clinical interest. MSC
have been shown in vitro to differentiate into adipocytes,
chondrocytes, osteoblasts, and myocytes [16,17]. MSCs
have also been shown to have immuno-modulatory
properties that, dependant on the MSC source and treat-
ment context, may demonstrate diverse effects from aid-
ing tissue repair [18] to promoting tumour formation [19].
Due to the ease of MSC harvest (e.g., via liposuction),
as well as their differentiation and immunomodulation
properties, a large number of MSC-based clinical trials
are progressing based on both their potential for
pharmaceutical action or cell-replacement [2,20]. How-
ever, variations in protocols used for MSC purification,
the lack of a definitive and universal MSC marker, and a
Figure 1 Key features that distinguish unproven stem cell therapies from other accepted cell treatments or investigations (Reproduced
with permission from The Australian Stem Cell Handbook).
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Table 1 Summary of some clinically relevant stem cell types and properties
Stem cell categories Examples of specific stem cell types Stem cell sources Properties/Challenges
Pluripotent stem cells Embryonic stem cells (ESCs) Induced
pluripotent stem cells (iPSCs)
Surplus human IVF blastocysts
(ESCs) Reprogrammed somatic
cells (iPSCs)
Can produce any cell in the body (ESCs, iPSCs)
Unlimited self-renewal capacity in vitro
(ESCs, iPSCs)
Difficult to generate pure populations of mature
cells with current culture conditions (ESCs, iPSCs)
Perceived ethical issues with some community
groups (ESCs)
Can be used for autologous (iPSC) or allogenic
(ESC, iPSC) treatment
Tissue-specific stem cells Hematopoietic stem cells (HSCs)
Skin stem cells (SSCs) Mesenchymal
stem cells (MSCs)
Bone marrow (HSCs, MSCs)
Peripheral blood (HSCs)
Normally produce only cells from the particular
tissue in which they are found
Skin (SSCs) Typically have limited self-renewal and expansion
capacity in vitro with current culture conditions
Fat (MSCs)
Cartilage (MSCs) Difficult to generate pure populations of mature
cells with current culture conditions
Can be used for autologous or allogenic
treatment
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settings currently make it difficult to interpret and com-
pare much ‘MSC’ research and clinical data [21,22]. Ef-
forts to overcome these limitations are underway, such
as the proposed use of minimal criteria for characteriza-
tion of MSCs in order to improve both intra- and inter-
laboratory data comparisons [23].
Autologous (patient-sourced) transplantation or in vivo
activation of tissue-specific stem cells offers an opportun-
ity to develop therapies without requiring immunomodu-
lation. However, historic and continuing difficulties in
purifying, maintaining and/or expanding tissue-specific
stem cells in vitro has hampered development of novel
therapeutic approaches using these cells. Moreover, the
fact that tissue-specific stem cells can each only make a
limited number of mature cell types makes production of
complex tissues from these cells challenging. To overcome
these significant practical limitations of tissue-specific
stem cells, alternative sources of stem cells with greater
developmental potential have been investigated. As a re-
sult, a variety of methods have been found for producing
human pluripotent stem cells that are capable of generat-
ing any cell type in the body. These include: embryonal
carcinoma cells derived from teratocarcinomas [24]; em-
bryonal germ cells [25]; embryonic stem cells derived from
donated supernumery preimplantation blastocysts [26] or
somatic cell nuclear transfer [27]; and, perhaps most re-
markably, induced pluripotent stem cells typically created
by introducing expression of four exogenous ‘reprogram-
ming factors’ into nucleated somatic cells [28]. Import-
antly all of these human pluripotent stem cells, with the
exception of embryonal carcinoma cells, can be main-
tained indefinitely in the laboratory with normal karyotype
to provide a scalable source of normal (or diseased)human cells for research and clinical applications. The de-
velopmental potential, extensive proliferative ability, and
economies of scale provided by human pluripotent stem
cells confer enormous clinical potential to these cells
(Table 1). However, the likely need for immunosuppres-
sion when transplanting their differentiated progeny pro-
vides a clear avenue for transplantation of autologous
tissue-specific stem cells. As described in the next section,
it remains to be seen which stem cell type (or types) will
provide viable clinical therapies for particular diseases.
Clinical trial of emerging stem cell therapies
Key to developing any new cell therapy from tissue-
specific or pluripotent stem cells is to identify, purify
and in some cases expand the most appropriate stem or
differentiated cell type (Figure 2). At the same time un-
wanted side-effects, such as transplantation of inappro-
priate or tumorigenic cells, need to be avoided. This
requirement presents a common challenge for both
tissue-specific and pluripotent stem cells since iterative
experimentation is required to: i) identify the optimal
cell type for disease intervention, and ii) establish appro-
priate conditions to generate and purify a clinically use-
ful number of the required cell(s) [29-33]. A range of
related considerations (and their influencing factors) that
need to be addressed during development of stem cell-
based clinical trials are listed in Table 2.
A recent review of the global landscape of stem cell
clinical trials shows ‘novel’ applications - trials that do
not involve established stem cell therapies - have grown
dramatically, particularly using tissue-specific stem cells
[2]. Stem cell companies, hospitals and research institu-
tions are supporting cell-based clinical trials for treat-
ment of stroke, myocardial infarction, inflammatory
Figure 2 Schematic of the development pipeline for stem cell therapies.
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spinal cord injury and macular degeneration. Many dif-
ferent stem cell sources, including fetal tissue, umbilical
cord, and adipose tissue are being investigated, with the
majority of the trials currently underway involving MSCs
from various sources [2]. It should be noted, however, that
due to the many unknowns surrounding MSC purification
and mechanism described above, some leading stem cell
clinician scientists have questioned the scientific basis and
patient merits of some of these MSC trials [1,22].
In contrast, the first clinical trial to be approved
worldwide using cells derived from human pluripotent
stem cells received approval from the USA Food and
Drug Administration (FDA) in 2010. This Phase I trial
used human embryonic stem cell-derived oligodendro-
cyte precursor cells to treat acute spinal cord injury. Un-
fortunately, despite the immense effort invested in
navigating the FDA regulatory requirements to establish
this ‘first in man’ trial, in 2011 it fell victim to the high
costs involved [34]. The company running the trial
(Geron Corporation) made a controversial strategic deci-
sion to halt new enrolments, though the patients treated
to this point continue to be monitored. This decision
was made so the company could concentrate their re-
sources on their anti-cancer platform. The decision
came as a harsh blow to many researchers and patients
who had been waiting for the opportunity to evaluate
this new approach. It also raised important ethical ques-
tions such as the obligation to secure sufficient funds to
complete a stem cell clinical trial.
Since commencement of the Geron trial two other hu-
man embryonic stem cell-based trials have begun and
others are planned. The two commenced trials are using
embryonic stem cell-derived retinal pigment epithelium to
treat dry, age-related macular degeneration and Stargardt’s
macular dystrophy [35]. In 2013 the trial expanded fromthe USA to Europe, though it is unclear from the short-
term patient data whether the transplanted cells have ob-
jectively improved visual acuity in the treated patients
[35,36]. Approval has also recently been obtained in Japan
for the first clinical pilot study using retinal pigment epi-
thelium derived from human induced pluripotent stem
cells [37]. Rather than using one donor cell source to treat
multiple patients (as with the human embryonic stem
cell-based trials), this induced pluripotent stem cell trial
will provide patients with in vitro produced autologous
cells. Six patients will have biopsies taken for induced
pluripotent stem cell production, from which retinal pig-
ment epithelial cells will be differentiated, purified and
seeded onto a cell substrate for transplantation. This
process will be time, labour and cost intensive, with it ex-
pected to take 10 months before the grafts are ready for
transplantation. Given that human induced pluripotent
stem cells were only first described in 2007 [28] it is a re-
markably short time to now be at the cusp of clinically
testing these cells. However, it remains to be seen whether
this type of highly technical and individualized patient-
specific treatment is practical, effective and financially
viable.
Unmet patient needs and the emergence of unproven
commercial therapies
The complexity of many incurable conditions, together
with our insufficient understanding of normal and ab-
normal biology, means that it will be years before many
who hope to benefit from stem cell therapies will be able
to participate in clinical trials. Moreover, while hundreds
of registered stem cell-based clinical trials are currently
underway for a wide range of conditions [2], the major-
ity of these are in the early-phase of testing to establish
the safety of the proposed interventions. As a result, the
number of patients able to participate is limited and
Table 2 An indicative and interconnected list of some considerations to be addressed during the iterative clinical trial development process
1. Transplant cells and method:
what disease stage should be
targeted; what cell type(s) will
produce the best outcome;
what stem cell source is most
appropriate for producing the
cell of interest (i.e., tissue-
specific or pluripotent); what
cell formulation will produce
the best outcome (single cell
type, 3D tissue, +/− scaffold);
where should the stem cell-
derived cells be transplanted;
how many cells or what sized
tissue is needed; how should
the transplant be delivered
(directly to site or will cell
homing be required); Good
Manufacturing Practice
manufacturing considerations;
cost and timeframe for cell har-
vest, expansion, storage, trans-
port and transplant preparation
(do these fit the disease/injury
repair timeframe); how to
monitor/track the transplanted
cells
2. Autologous vs. allogenic cells:
are cells obtained directly from
the patient (autologous) more
appropriate than those from a
donor (allogeneic); do
appropriate methods exist for
either stem cell source to
generate sufficient purified
cells for transplantation; cost
and timeframe for cell harvest,
expansion and transplant








3. Avoidance of tumorigenicity:
do the target transplant cells
have intrinsic tumor forming
potential; how to ensure
residual unwanted cells with
tumor forming potential are
absent from the transplant (e.g.,
residual pluripotent stem cells);
could the transplant
environment induce aberrant
proliferation of the transplanted
cells; how will potential
tumorigenicity be managed
4. Navigating the regulatory
environment: where will the
clinical trial be conducted; what




(i.e., will the grafted cells
perform exactly the same
function as their endogenous
normal counterparts or not);
degree of manipulation of the
cells ex vivo; relevance and risk
associated with ‘fast-tracking’
approval of new treatments;
‘compassionate’ use and
medical innovation
5. Ethical oversight: how will
patients be recruited and at
what stage of the disease; how
will patients be informed
about the cell type to be used,
the expected scientific/
mechanistic basis of the
treatment and associated
animal or human evidence for
this; what consent will be
required; what cells will be
transplanted and how; how
will treatment efficacy/side-
effects be monitored and
measured; what human
research ethics committee is
appropriate/required; what
arrangements are in place to
contend with adverse outcome
and ongoing care; how will the
patient’s condition be
monitored; how will data be
collected and shared
6. Infrastructure and leadership:
cell therapy training and
clinical expertise of those
conducting the clinical
research; need for specialist
centres and equipment
including Good Manufacturing
Practice expertise and facilities;
medical insurance to provide
support in the advent of
adverse outcomes; key
leadership for integration of
procedures; support personnel
required for recruitment,
patient counseling and clinical
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that many patients feel they are denied access to treat-
ment. Rather than waiting to participate in clinical trials
or waiting for the outcomes of these trials, many pa-
tients are prepared to risk pursuing unproven stem cell
treatments outside of clinical trials and often without
scientific basis, adequate safety data, or ethical and regu-
latory scrutiny [38-40]. Promoted on impressive-looking
websites, these unproven therapies often make use of
moving patient testimonials to attract patients but have
very little in the way of evidence to support the claimed
benefits [41,42].
These unproven stem cell ‘treatments’ include the use
of autologous and allogenic stem cell transplants, and
are estimated to attract thousands of patients from
around the world each year [43]. Until recently, these
unproven treatments have typically involved travel to
countries with less stringent regulation of experimental
stem cell treatments. Such travel is often dubbed ‘stem
cell tourism’ [44] and has raised great concern within
the international stem cell community [45] due to the
potential for real harm that may befall patients under-
taking the treatments. Indeed, complications including
meningitis [46], encephalomyelitis [47], tumours [48,49],
aberrant bone formation [50] and at least two reported
deaths [51,52] have all been attributed to unproven stem
cell treatments.
More recently, there has been growth in the number
of clinics selling treatments using a patient’s own cells in
countries with considerable regulation such as Australia
and the USA [53]. Regularly but inaccurately marketed
as having ‘no risks’, being ‘natural’, or being accepted
medical practice, these unproven therapies routinely lack
credible scientific evidence or overstate/inappropriately
extrapolate the significance of animal data or prelimin-
ary human studies. In stark contrast to the ground-
breaking but experimental hematopoietic and skin stem
cell treatments that first occurred in the 1950s and 1980s
respectively, these modern commercially-marketed un-
proven therapies typically have little or no patient follow-
up and provide no data to further international research
efforts into treatment development.
Proponents of unproven commercial therapies argue
that a patient should have the right to pursue treatment
using their own cells and blame over-regulation for
delaying clinical progress of stem cell treatments [54,55].
Even 2012 Nobel Prize winner in Physiology and Medi-
cine, Sir John Gurdon, has criticised the FDA for placing
"immense conditions on approval" saying "I think pa-
tients would be happy to take the risk of using their own
cells given the choice" [56]. In contrast others are con-
cerned that early adoption of unproven stem cell inter-
ventions, outside ethical review and the clinical trials
processes, places individuals at risk of personal harm.Such unproven stem cell interventions also raise the sig-
nificant risk of placebo effects being mistaken for genu-
ine cures, and could stymie progress in the field. A
recent statement from the International Society for Stem
Cell Research (ISSCR) has urged ‘medical licensing bod-
ies, legal authorities, patient advocacy organizations,
physicians, and others to exercise their influence to dis-
courage commercial provision of unproven autologous
cell-based interventions outside of clinical trials’ [57].
Evolving regulatory frameworks for stem cell therapies
Although there is still a role for assessment of innovative
medical treatment using unproven stem cell interven-
tions - like the initial 1957 hematopoietic and 1981 skin
stem cell grafts - this approach should be considered as
a ‘one-off ’ and not offered widely or commercially until
proven safe and effective. As recommended by the
ISSCR this approach should only occur when certain
conditions are satisfied such as: a robust scientific ra-
tionale; peer review of the proposed approach; data col-
lection and clinical follow-up; undertaking only to treat
a small number of patients who have provided informed
consent; and commitment to more formal clinical trials
in a timely manner (Figure 1).
Attempts to incorporate these recommendations while
also decreasing the time for translating stem cell therap-
ies are already underway. For example, recent legislation
has provided the USA FDA with a new breakthrough
therapy designation that offers the possibility of acceler-
ated approval for investigational new drugs for serious
conditions [54]. In late 2013 Japan approved two new
pieces of legislation: one that requires physicians to re-
port the use of unapproved stem cell therapies to the
health ministry, and another that creates a new approval
channel for regenerative medicine and stem cell therap-
ies [58,59]. This new approval process appears similar to
one used in South Korea, and also appears to be a vari-
ation of the currently accepted ‘medical innovations’ route
of therapeutic development (Figure 1). At this stage
though, a variety of important issues remain unclear such
as: whether it will only be used to offer therapies to pa-
tients with no other viable alternatives; who will take re-
sponsibility for adverse outcomes; and what level of
expertise will be required by the treatment provider.
This new Japanese legislation will enable companies to
initiate small pilot treatment studies with as few as 10
patients without having to perform traditional Phase III
clinical trials. If some degree of efficacy is shown in the
pilot study, then the therapy can be approved for commer-
cial use for 5 to 7 years, with possible coverage through
the national health system. Once permission for commer-
cialisation has been granted all patient data must be cap-
tured in a treatment registry, and approval can be
withdrawn if therapies prove unsafe or ineffective.
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ful side-effects from emerging and unproven stem cell
therapies, it nevertheless has the potential to promote
the sale of unproven and potentially costly stem cell
therapies to desperate and vulnerable patients. It also
raises the potential for patients to bypass currently
available and effective treatments in favour of directly-
marketed unproven therapies. It may also lead to mis-
leading placebo effects becoming ingrained within the
field since commercial treatments cannot be supplied,
and their efficacy tested, as done with traditional
double-blind clinical trials. Additionally, should any
therapy commercialised in this way prove ineffective
(or worse, identify previously unknown harmful side-
effects), then large numbers of patients will have been
subjected to inappropriate risks associated with med-
ical procedures at significant health, financial and
emotional cost.
Conclusions
The pace of research into tissue-specific and pluripotent
stem cells continues to increase, with new advances an-
nounced regularly. In this review we see that solid foun-
dations of basic molecular research are required, not
necessarily for establishment of therapeutic concepts,
but for development of therapies towards safe and effect-
ive clinical treatments. From less successful applications
we see the dangers of unproven procedures and the
challenges in developing therapeutic regimes with lim-
ited molecular understanding. As the appearance of
stem cell-related clinical trials accelerates, failed trials
and possibly unforeseen side-effects are likely to follow.
At the same time there is a danger of harmful or fatal
consequences resulting from the emergence of profit-
driven unproven stem cell therapies that take advantage
of vulnerable patients. A concerted effort is therefore re-
quired to identify pitfalls and safeguards for timely and
effective clinical translation of emerging stem cell ther-
apies. Additionally it is not yet clear which stem cell
types will be best suited to treat particular diseases. Ul-
timately, only further empirical research will determine
for each disease whether optimal treatment is provided
by the extensive proliferative and differentiation poten-
tial of pluripotent stem cells, or the potential autologous
nature of tissue-specific stem cells.
To address these issues we need to continue to dili-
gently manage the expectation of patients and their
families and friends, as well as those of the media, gov-
ernments and financiers wanting to invest in the area.
This includes correcting the misunderstanding that any
source of stem cells is an automatic and unquestioned
panacea for all ailments.
We need to accelerate access for patients to well-
regulated and adequately funded clinical trials, but thesetrials need to be based on a detailed, mechanistic under-
standing of the disease process with strong supporting
pre-clinical data. We must also acknowledge that it is
going to take time to develop new stem cell treatments.
This will help to avoid academic, social and economic
pressures from eroding the integrity of, and community
confidence in, the regenerative medicine field. The re-
cent controversy surrounding the Stimulus-Triggered
Activation of Pluripotency (STAP) method [60] high-
lights this need, as well as the need for robust and trans-
parent oversight processes at all levels, from basic
research through to clinical translation.
We need to share results from all clinical research so
that further research can be undertaken to evolve or
develop promising new clinical therapies. We need to
provide opportunities for innovative medicine on com-
passionate grounds but prevent over-enthusiasts from
providing unproven and potentially unsafe procedures.
Enforceable frameworks need to be developed that en-
sure new or ‘novel’ stem cell treatments are at least first
proven safe through independent, peer-reviewed Phase
I and II clinical trials in order to define for the patient
the severity and frequency of unwanted side-effects.
We must ensure that any new therapy is provided only
with informed patient consent and rigorous long-term
post-treatment monitoring. We recommend that any
commercially available stem cell therapies not assessed
via Phase III clinical trials should be required to be des-
ignated as experimental treatments. It is only through
recognising and addressing these issues that the field will
safely progress at a rate closer to the expectations of pa-
tients, thus realising maximal patient benefits without
simply ‘selling hope’.
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